News, news, news (Seite 7)

eröffnet am 29.01.20 18:00:03 von
neuester Beitrag 08.04.21 19:47:09 von

Beitrag schreiben

Begriffe und/oder Benutzer



 Ja Nein
01.02.20 18:58:43
Antwort auf Beitrag Nr.: 62.554.169 von gl_77 am 01.02.20 18:05:30Nach was denn sonst?
Der Doc ist -wie gesagt- eine Koryphäe...
Und die anderen genannten Firmen sind auch nicht schlecht...Eine datiert bei 180€...
WPD Pharmaceuticals | 1,250 €
01.02.20 19:16:23
Kaufe nicht bevor der pollinger nicht verschwindet, werde jede Aktie meiden wo der Typ seine Finger drin hat sollte jeder machen. Hoffe er liest das
WPD Pharmaceuticals | 1,250 €
1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
01.02.20 19:26:41
Antwort auf Beitrag Nr.: 62.554.523 von Achim1967 am 01.02.20 19:16:23
Hier die original Meldung... Nix Pollinger
WPD Pharmaceuticals Completed the Acquisition of Two Pancreatic Cancer Drug Candidates
VANCOUVER, British Columbia, Jan. 31, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, provides this update on the completed acquisition of exclusive sublicenses for two drug candidates from Moleculin Biotech, Inc. (Nasdaq: MBRX) a leading global pharmaceuticals company focused on the treatment of highly resistant cancers. The territory covered by the patents includes 30 countries in Europe and Asia, including Russia.

The licensed drug candidates, WP1122 and WP1732, are both considered promising potential therapies for treating pancreatic cancer, among other highly resistant tumors. WP1732 appears capable of a disproportionately high accumulation in the pancreas, making it a promising candidate for treating pancreatic cancer. WP1122 is capable of inhibiting glycolysis, a process by which cells convert glucose into energy and one on which many tumor cells are known to be much more dependent for their survival than normal cells. In particular, pancreatic cancer is known to be highly dependent on glycolysis.

The incidence of and number of deaths caused by pancreatic cancer have been gradually rising, even as the incidence and mortality of other common cancers have been declining. Removal of the pancreatic cancer tumor is currently the only chance of cure. Unfortunately, 80% to 85% of patients diagnosed with pancreatic cancer are at an advanced stage and the tumor has overtaken the pancreas and even surrounding tissues. Furthermore, pancreatic cancer responds poorly to most chemotherapeutic agents.

Mariusz Olejniczak, CEO of WPD commented, “The Acquisition of these two pancreatic cancer drug candidates is an important step for WPD, and continues to demonstrate our ability to execute on our long term strategy of developing novel treatments for cancer. Working with some of the world’s leading cancer scientists, we are diligently focused on developing our portfolio of eight drugs across five different indications. We will continue working with Moleculin to further develop these drug candidates in our ongoing effort to create improved treatments for pancreatic cancer and other highly resistant tumors.”

The Company also announces that on January 29, 2020 it granted 200,000 options to a new member of its scientific advisory board. The options are exercisable for 5 years at an exercise price of $1.23 per share.

About WPD Pharmaceuticals

WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including MD Anderson Cancer Center, Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things.

On Behalf of the Board

‘Mariusz Olejniczak’

Mariusz Olejniczak
CEO, WDP Pharmaceuticals


Investor Relations
Tel: 604-428-7050

Cautionary Statements
WPD Pharmaceuticals | 1,250 €
01.02.20 19:29:06
Antwort auf Beitrag Nr.: 62.554.433 von Camus70 am 01.02.20 18:58:43Bilanzberichte und Fillings, PR kann jeder!
WPD Pharmaceuticals | 1,250 €
01.02.20 19:30:16
Antwort auf Beitrag Nr.: 62.554.523 von Achim1967 am 01.02.20 19:16:23
Zitat von Achim1967: Kaufe nicht bevor der pollinger nicht verschwindet, werde jede Aktie meiden wo der Typ seine Finger drin hat sollte jeder machen. Hoffe er liest das

Er wird sich aber nicht abmelden! 😉
WPD Pharmaceuticals | 1,250 €
01.02.20 19:31:56
Antwort auf Beitrag Nr.: 62.554.559 von NiewiederFerkel am 01.02.20 19:26:41@NiewiederFerkel, was können wir daraus lesen?
WPD Pharmaceuticals | 1,250 €
01.02.20 20:04:07
Bullinvestor lesen lohnt sich nicht.
WPD Pharmaceuticals | 1,250 €
01.02.20 20:05:14
Die Aktie an sich schon nur abwarten pollinger pusht schon für Montag. Finger weg
WPD Pharmaceuticals | 1,250 €
01.02.20 20:23:16
Antwort auf Beitrag Nr.: 62.554.523 von Achim1967 am 01.02.20 19:16:23Da legst du den Finger in meine Wunde...
Das ist genau auch mein Problem....
WPD Pharmaceuticals | 1,250 €
01.02.20 21:31:33
Beobachten und den Depp machen lassen, nur nicht auf den Trick reinfallen spart euer Geld
WPD Pharmaceuticals | 1,250 €

Beitrag zu dieser Diskussion schreiben

News, news, news